peppersite
Peptidesubcutaneousoral

KPV

KPV is a tripeptide derived from the C-terminal of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13), studied in anti-inflammatory and gut-barrier research models.

Researched for
InflammationGut HealthTissue RepairRecovery
Not yet audited

We have not published an audit on KPV. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Potential anti-inflammatory signaling via melanocortin pathways.

KPV is a tiny three-amino-acid fragment of a natural hormone that reduces inflammation, especially in the gut, by calming specific inflammatory signals (like NF-kB) without broadly suppressing the immune system, and it can be taken orally because a gut transporter called PepT1 absorbs it, with more of that transporter present in inflamed tissue.

Reported side effects

KPV is generally reported as well-tolerated, with the most commonly noted effects being mild injection-site irritation, occasional mild headache, and occasional GI upset at higher oral doses, though no formal human safety trial has been completed.

Who should avoid it

People who are pregnant or breastfeeding, have a known peptide hypersensitivity, have active complex infections, or are on prescription immunomodulators for autoimmune or inflammatory bowel disease should avoid KPV or consult a clinician before considering it.

What gets monitored

Monitor symptom-level changes, injection-site condition, oral GI tolerance, and any new symptoms that prompt review with a clinician. [Source: Peptide Dosing Protocols]

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for KPV or for anything else, and nothing below has been checked against the study it came from.

200-500 mcg SC daily, or 250-500 mcg orally twice daily for gut-directed support
Frequency
once daily (SC) or twice daily (oral)4-8 weeks · 4-8 week cycles
Route
subcutaneous or oral
Reported by
Commonly published practitioner dosing range - provider confirmation required.
200-500 mcg per injection (SC); or oral capsules as directed
Frequency
Once daily (SC); 1-2 times daily (oral)
Route
subcutaneous or oral
Reported by
Peptide Protocol Wiki
What it says(secondary reference; provider confirmation required).
Standard: 200-500 mcg once or twice daily · Low: 200 mcg/day SubQ · High: 500 mcg twice daily
Frequency
once or twice dailyWeeks 1-8+ · 4-8 weeks on, 2-4 weeks off
Route
oral, subcutaneous
Reported by
Peptide Dosing Protocols
What it says(secondary reference; provider confirmation required). KPV is commonly dosed at 200-500 mcg once or twice daily for gut health.
Reconstitution, as reported
  • Commonly 5 mg vials (injectable) or oral capsules · Reconstitute with bacteriostatic water (injectable form)
  • Bacteriostatic water
  • 2 mL BAC water

Common questions

What is KPV peptide?

KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the C-terminus of alpha-MSH, the body's natural anti-inflammatory hormone.

What are KPV peptide benefits in research?

Preclinical and laboratory research has reported anti-inflammatory effects, antimicrobial activity, and skin-inflammation effects.

What is the KPV peptide dosage in research planning?

The most-discussed range is 200-500 mcg daily, used either orally or subcutaneously.

How is KPV reconstituted?

A common setup is 10 mg of lyophilized KPV with 2 mL of bacteriostatic water.

Check 10 mg in 2 mL in the calculator →

Can KPV be taken orally?

Yes, oral KPV is a common research route, especially for gut-focused work.

What are KPV's main side effects?

Community reports are usually mild: transient injection-site irritation, occasional mild headache, and occasional GI discomfort.

Does KPV cause tanning or pigmentation changes?

No, KPV does not bind the melanocortin receptors that drive pigmentation.

Is KPV FDA approved in 2026?

No, KPV is not FDA-approved.

Sources

The reference sections above are imported from our compound knowledge base, which classes the evidence for KPV as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.

Studied for the same things